Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Percutaneous coronary intervention (PCI)-related myocardial infarction (MI), especially the distal type associated with microvascular dysfunction, is not an uncommon complication of the procedure. Specific lesion features, the echo-attenuated plaques (EA) in particular, are well-established contributors to the pathogenesis of distal-type MI. These plaques are prone to disruption during PCI, leading to microvascular thrombosis and distal embolism. Tenecteplase (TNK), a 3rd-generation thrombolytic drug, has demonstrated effective thrombolytic capacity without significantly increasing the bleeding risk. Our study aims to evaluate whether a low-dose intracoronary TNK administration prior to PCI in patients with intravascular ultrasound (IVUS)-detected EA can reduce the occurrence of PCI-related MI and improve clinical outcomes.
Methods: This trial is designed as a multicenter, prospective randomized controlled trial with a 1-month follow-up. The primary outcome of the study is the incidence of PCI-related myocardial infarction (MI) occurring within 48 h after PCI, which serves as a valid surrogate endpoint for assessing the efficacy of tenecteplase-based PCI in preventing future major adverse cardiovascular events (MACE) in patients with EA (Bulluck, et. al, Eur Heart J 42:2630-42, 2021) {1b.1}. Secondary outcomes include the proportion of patients with elevated postoperative high-sensitivity cTnI exceeding 5, 10, 35, and 70 times of the normal baseline, incidence of coronary slow flow after stent implantation and post-dilation, frame count of angiographic flow after stent implantation and post-dilation, as well as the incidence of MACE during hospitalization and at the 1-month follow-up.
Discussion: This trial may demonstrate that an immediate intracoronary administration of low-dose TNK following PCI can effectively lower the incidence of PMI in patients with EA, while confirming the safety of this therapeutic approach.
Trial Registration: Chinese Clinical Trial Registry ( ChiCTR2400084840 ). Registered on May 27, 2024.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587588 | PMC |
| http://dx.doi.org/10.1186/s13063-024-08605-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravascular Ultrasound Findings Associated With Hydrodynamic Contrast Recanalization (HDR) of Coronary Chronic Total Occlusions.
Catheter Cardiovasc Interv
September 2025
University of Texas, Houston, Texas, USA.
Background: Hydrodynamic contrast recanalization (HDR) is a novel technique to facilitate wire crossing during chronic total occlusion (CTO) percutaneous coronary interventions (PCI). The mechanisms underlying HDR have not been fully described.
Aims: To investigate the impact of HDR on plaque morphology and wire tracking during CTO PCI using intravascular ultrasound (IVUS) imaging.
Clinical, procedural, and follow-up outcomes of percutaneous coronary intervention-related stroke: insight from the PROGRESS-COMPLICATIONS registry.
J Invasive Cardiol
August 2025
Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota. Email:
Background: Stroke is an infrequent but potentially severe complication of percutaneous coronary intervention (PCI).
Methods: The authors describe the clinical features, angiographic characteristics, and procedural and follow-up outcomes of PCI-related stroke in the PROGRESS-COMPLICATIONS registry.
Results: Of 22 503 patients who underwent PCI at 2 tertiary care centers between 2016 and 2023, 157 (0.
A Delayed Sterile Abscess Following a Percutaneous Coronary Intervention (PCI)-Related Myocardial Injury Successfully Treated With an Omental Flap: A Case Report.
Cureus
June 2025
Cardiovascular Surgery, IMS Katsushika Heart Center, Tokyo, JPN.
Topical hemostatic agents are commonly used in cardiac surgery to achieve rapid hemostasis in fragile myocardial tissue, particularly following myocardial infarction or mechanical injury during percutaneous coronary intervention (PCI). While effective in the acute setting, retained hemostatic materials can lead to delayed complications, including sterile abscess formation. We present a case of a 77-year-old man who developed a sterile abscess one year and nine months after emergency surgical hemostasis for myocardial oozing following PCI.
View Article and Find Full Text PDFBackground: Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy compared with onsite fibrinolytic therapy (O-FT) for ST-segment-elevation myocardial infarction when delivered promptly. However, the contemporaneous data to inform the comparative benefits of primary PCI versus O-FT, especially in developing countries, have been largely understudied.
Methods: We used data from the National Chest Pain Center Program (NCPCP), the largest nationwide registry in China, including patients with ST-segment-elevation myocardial infarction treated with primary PCI or O-FT from January 2016 to December 2022.
Outcomes among patients with coronary bifurcation lesions undergoing Impella-supported high-risk percutaneous coronary intervention.
Am Heart J
December 2025
Division of Cardiology, Henry Ford Health System, Center for Structural Heart Disease, Detroit, MI. Electronic address:
Background: Coronary bifurcation lesions (CBL) are associated with lower procedural success, worse postprocedural outcomes, and greater unplanned repeat revascularization. We sought to better understand the impact of Impella support in patients undergoing percutaneous coronary intervention (PCI) of CBLs.
Methods: We used data from the cVAD PROTECT III study (NCT04136392), an FDA-audited, single-arm study of patients undergoing high-risk PCI with Impella support, to examine the outcomes of patients undergoing PCI of CBLs.